[en] Full text: Radiolabeled Hydroxyapatite nanoparticles (HAn) have been investigated as theranostic agents for bone cancers¹ due to its characteristics such as biocompatibility, bioactivity and affinity for bone tissues². These features allow the production of a nanocarrier that is able to deliver radiation doses specific in tumor sites. With the doping process it is possible to confine radioisotopes in hydroxyapatite crystalline structure, avoiding the releasing of radionuclides in bloody stream that could result in loss of affinity to tumor cells and increasing of radiation doses in normal tissues. Copper-64 is an important radioisotope for medical applications due to its dual emission of beta and positron radiations that allows its use as theranostic agent for many types of cancer, making possible the simultaneous treatment and diagnosis. In this work, ⁶⁴Cu was produced by the neutron irradiation of copper nitrate in TRIGA nuclear reactor at CDTN (Belo Horizonte), purified by radiochemical routes and ⁶⁴Cu-doped HAn were synthesized by hydrothermal method. The leaching test was conducted to study the confinement of Cu ions in HAn matrix. To elucidate the nanoparticles properties, the materials were characterized by XRD with Rietveld refinement, FTIR, MEV, TEM, XPS and gamma spectroscopy techniques. Preliminary in vitro biological tests were conducted through MTT and Live/Dead assays with human fibroblasts and human osteosarcoma cell linage. The results indicate that HA[⁶⁴Cu] nanoparticles can be produced with radiochemical purity and high specific activity with no significant copper ions releasing from HA matrix. The biological tests indicate that these nanoparticles are able to kill bone tumor cells, crediting this material for extensive biological tests. References: 1. Cipreste, M. F. et al. Ceram. Int. 44, 17800–17811 (2018); 2. Wu, X. et al. J. Bionic Eng. 9, 224–233 (2012). (author)